Human Genome Sciences deal

As amended, HGSI may submit to SmithKline four special therapeutic protein proposals per quarter, and will have exclusive rights to develop or outlicense a maximum of six of the designated proteins per year, for use as bioactive protein drugs. The proposals will be based on human genes discovered by the collaboration. SmithKline will receive royalties from HGSI on net sales of any therapeutic proteins developed or outlicensed.

One protein will be selected each quarter, and two more at year end. HGSI said it already has been assigned rights to one such protein. ...